Form 4: Spero Therapeutics Director Milind Deshpande Granted 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director Milind Deshpande was granted 20,000 restricted stock units (RSUs) on June 12, 2025, increasing his total beneficial ownership to 91,454 shares.

Summary

• Milind Deshpande, a Director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock.
• The acquisition occurred on June 12, 2025, and was in the form of Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs were granted at a price of $0.00 per unit, indicating they are part of an equity compensation plan.
• These RSUs are scheduled to vest on June 12, 2026, contingent upon Mr. Deshpande's continued service to the company.
• Following this transaction, Milind Deshpande's total beneficial ownership of Spero Therapeutics common stock stands at 91,454 shares.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a positive for aligning interests but does not provide new operational or financial performance data. It's a routine, expected event.

Positives

• The grant of restricted stock units to a director aligns their interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• This transaction represents a standard form of equity compensation for board members, indicating ongoing commitment and incentivization.

Future Outlook

The 20,000 Restricted Stock Units granted to Director Milind Deshpande are scheduled to vest on June 12, 2026, provided he continues his service to the company.

Industry Context

This transaction is a routine insider filing (Form 4) detailing an equity compensation grant to a director, which is a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to incentivize and retain key personnel.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of equity compensation for directors is a widely adopted practice across industries, including biotechnology and pharmaceuticals.
• RSUs are a standard mechanism to align the long-term interests of directors with those of shareholders, similar to compensation structures seen at comparable companies in the biotech space.

Corporate Governance

Related Party Transactions

• Grant of 20,000 restricted stock units to Director Milind Deshpande as part of his compensation, which is a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the compensation is tied to the company's stock performance.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for equity-based incentives within the company.

Next Steps

• Vesting of the 20,000 Restricted Stock Units on June 12, 2026, subject to continued service.

Key Dates

Keywords

Spero Therapeutics, SPRO, Milind Deshpande, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, equity grant